Integra LifeSciences Applauds Policy Developments Enhancing Access for Medicare Beneficiaries

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 25 2025

0mins

Source: Globenewswire

Integra LifeSciences Commends CMS: Integra LifeSciences praises the Centers for Medicare & Medicaid Services for including its dermal regenerative templates and other skin substitutes in the 2026 Medicare Physician Fee Schedule, which will enhance access to their innovative wound reconstruction products.
Impact on Innovation and Patient Care: The new reimbursement structure is expected to reward innovation and improve patient outcomes, allowing Integra to expand its commercial presence and positively impact the procedural landscape in healthcare.
Diverse Product Portfolio: Integra's offerings, including the flagship Integra Dermal Regeneration Template, utilize various technology platforms and are supported by clinical evidence, making them a cost-effective solution for complex wound reconstruction cases.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the potential commercial impact of the new reimbursement rates, while also acknowledging the risks and uncertainties that could affect Integra's business performance.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.